As of Feb 22
| -0.10 / -3.85%|
The 1 analysts offering 12-month price forecasts for Imprimis Pharmaceuticals Inc have a median target of 5.00, with a high estimate of 5.00 and a low estimate of 5.00. The median estimate represents a +100.00% increase from the last price of 2.50.
The current consensus among 1 polled investment analysts is to Buy stock in Imprimis Pharmaceuticals Inc. This rating has held steady since February, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.